Clinical Trial Results

April 8, 2026

Patients with CLL can be Retreated with Venetoclax

Black and Hispanic patients with CLL were less likely than White patients to be prescribed guideline-recommended novel therapies.

February 17, 2026

Pirtobrutinib Versus Ibrutinib for Treating CLL

In the first head-to-head comparison, patients with CLL who were treated with either pirtobrutinib or ibrutinib responded equally well to both treatments.

January 27, 2026

First-Line Pirtobrutinib Versus Chemoimmunotherapy

Pirtobrutinib as a first-line therapy significantly improved progression-free survival in patients with CLL / SLL compared with chemoimmunotherapy.

January 21, 2026

Second-Line Therapies After Fixed-Duration Treatments

Second-line targeted therapies are very effective for patients with CLL who relapse after first-line, fixed-duration venetoclax-based therapy.

July 24, 2025

Phase 1 Clinical Trial of a New BTK Degrader for CLL

NX-5948 is a novel type of drug, classified as a BTK degrader, and it has shown promising early clinical data.

June 9, 2025

MRD-Guided Ibrutinib Plus Venetoclax Therapy for CLL

MRD-guided ibrutinib plus venetoclax is a very effective combination therapy for treating CLL, and it can provide durable responses.

May 2, 2023

ASH 2022: Dr. Mazyar Shadman on Enitociclib, a CDK9 Inhibitor, for Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

We discuss enitociclib, an experimental CDK9 inhibitor in development for treating NHL and CLL.

February 15, 2023

ASH 2022: Dr. James Blachly Discusses Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-533, a Novel and Selective Protein Kinase C-Beta Inhibitor in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

MS-553, a protein kinase C-beta (PKCß) inhibitor, is an exciting new agent in a yet-to-be-approved class of drugs that target an area of the B-cell receptor pathway independent of Bruton tyrosine kinase (BTK) and phospholipase C gamma 2 (PLCy2) mutations which confer resistance to BTK inhibitors.

February 6, 2023

ASH 2022: Dr. Parag Jasani on NVG-111, a ROR1 Targeting Bispecific T Cell Engager, for Chronic Lymphocytic Leukemia (CLL)

Our own Dr. Brian Koffman interviewed Dr. Parag Jasani, a consultant hematologist with Royal Free London NHS Trust and University College London Hospitals. They discussed a first-in-human study of an experimental drug, NVG-111, a bispecific T cell engager. NVG-111 binds to ROR1 on cancer cells and CD3 on T

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.